FLIXONASE ® is a drug based on Fluticasone propionate
THERAPEUTIC GROUP: Rhinological - Nasal decongestants and other preparations for topical use
IndicationsAction mechanismStudies and clinical effectiveness Usage and dosage instructionsWarnings Pregnancy and lactationInteractionsContraindicationsUndesirable effects
Indications FLIXONASE ® Fluticasone
FLIXONASE ® is indicated in the prophylaxis and symptomatic treatment of seasonal and chronic allergic rhinitis.
Mechanism of action FLIXONASE ® Fluticasone
FLIXONASE ® is a medicinal product based on Fluticasone propionate, a synthetic corticosteroid characterized by an important local therapeutic activity.
Its pharmacokinetic characteristics, and in particular the low degree of systemic absorption following the topical use of the product, make it the ideal candidate for the treatment of local inflammatory diseases.
In fact applied by nasal spray, Fluticasone carries out its therapeutic activity directly at the level of the nasal mucosa, significantly reducing the inflammatory degree of the microenvironment by controlling the secretion of inflammatory cytokines and adhesion molecules.
In addition to a strong anti-inflammatory activity, Fluticasone also performs an antiallergic action in the early stages, guaranteeing effective control of the edema and congestion that occurs periodically in diseases such as seasonal allergic rhinitis.
Studies carried out and clinical efficacy
FLUTICASONE IN ASTHMA TREATMENT
Eur Respir J. 2013 Oct 17. [Epub ahead of print]
O'Byrne PM, Bleecker ER, Bateman ED, Busse WW, Woodcock A, Forth R, Toler WT, Jacques L, Lötvall J.
Recent study that demonstrates how the inhalation of Fluticasone can determine an effective improvement of the ventilatory capacities, in patients suffering from asthma, especially when taken in association with agonists of long-acting B2 receptors.
CLINICAL EFFECTIVENESS OF FLUTICASONE IN THE TREATMENT OF CHRONIC RENOSINUSITIS
Int Forum Allergy Rhinol. 2013 Oct 2. doi: 10.1002 / alr.21228. [Epub ahead of print]
Man LX, Farhood Z, Luong A, Fakhri S, Feldman RM, Orlander PR, Citardi MJ.
A study that demonstrates how the intranasal irrigation of Fluticasone in the treatment of chronic rhinosinusitis, can guarantee pharmacokinetic and clinical advantages compared to other drugs such as Budesonide, reducing some complications such as increased intracular pressure.
FLUTICASONE CLINICAL SAFETY
Br J Clin Pharmacol. 2013 Oct 4. doi: 10.1111 / bcp.12243. [Epub ahead of print]
Kempsford R, Allen A, Kelly K, Saggu P, Crim C.
Phase III clinical trial demonstrating how daily mono-administration of Fluticasone, even when combined with other drugs such as Vilanterol, does not result in prolongation of the QT interval in healthy individuals.
Method of use and dosage
FLIXONASE ®
Nasal spray from 0.05 g of Fluticasone propionate per 100 g of product.
The definition of the therapeutic scheme and the dosage of FLIXONASE ® to be used must be established by the doctor on the basis of the patient's health conditions and the related therapeutic objectives.
As a rule, in adults, two applications per nostril are recommended once a day, preferably in the morning.
Halved dosages are instead provided for smaller patients and in particular for children under 12 years of age.
Warnings FLIXONASE ® Fluticasone
FLIXONASE ® therapy must necessarily be defined and supervised by a doctor in order to periodically assess the clinical efficacy of the same and the possible occurrence of side effects.
In fact, it is worth remembering how the prolonged use of this drug could determine the onset of local pathological conditions, characterized by reactions from hypersensitivity to the drug.
The possible presence of infections should alarm the doctor, suggesting the need to establish an appropriate antibiotic or antiseptic therapy.
Furthermore, the doctor should pay particular attention to pediatric patients taking FLIXONASE ®, making sure that the growth takes place under normal physiological conditions.
PREGNANCY AND BREASTFEEDING
The absence of studies able to characterize the safety profile of the Fluticasone on the fetus and on the suckling extend the contraindications to the use of FLIXONASE ® also to the pregnancy and to the following period of breastfeeding.
Interactions
Despite the systemic absorption of Fluticasone that follows the use of FLIXONASE ® is almost nil, it is important to remember that inhibitors or inducers of the cytochromial system can alter their normal pharmacokinetic characteristics, thus making their action unpredictable.
Contraindications FLIXONASE ® Fluticasone
The use of FLIXONASE ® is contraindicated in patients with hypersensitivity to the active ingredient or to one of its excipients and in patients suffering from local viral and tubercular infections.
Undesirable effects - Side effects
FLIXONASE ® therapy, especially when it lasts for a long time, could lead to the appearance of side effects such as headache, epistaxis, nasal irritation, dryness and irritation of the throat.
Fortunately, the systemic side effects that are worthy of note are rarer.
Note
FLIXONASE ® is a drug subject to mandatory medical prescription.
